In addition, several other approaches developed CRISPR/Cas9-mediated PD1-disrupted CAR-T cells and CTLA-4–specific CAR-T cells to improve effector function of CAR-T cells and enhance their anti-tumor activity (130). Here, CTLA4 is linked to neoplasm.